{
    "xml": "<topic id=\"PHP6626\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/abatacept\" basename=\"abatacept\" title=\"ABATACEPT\">\n<title>ABATACEPT</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1095\" namespace=\"/interactions/list-of-drug-interactions/abatacept\">Abatacept</xref>\n</p>\n<data name=\"vtmid\">421412005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_876737053\" title=\"T-cell activation inhibitors\">T-cell activation inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP65230\" outputclass=\"indicationsAndDose\" rev=\"1.57\" parent=\"/drugs/abatacept\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Moderate to severe active rheumatoid arthritis (in combination with methotrexate) in patients unresponsive to other disease-modifying antirheumatic drugs (including methotrexate or a tumour necrosis factor (TNF) inhibitor)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight up to 60 kg)</p>\n<p>500&#8239;mg every 2&#8239;weeks for 3 doses (loading dose), then (by intravenous infusion) 500&#8239;mg every 4&#8239;weeks, alternatively (by subcutaneous injection) 125&#8239;mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 60&#8211;100 kg)</p>\n<p>750&#8239;mg every 2&#8239;weeks for 3 doses (loading dose), then (by intravenous infusion) 750&#8239;mg every 4&#8239;weeks, alternatively (by subcutaneous injection) 125&#8239;mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 101 kg and above)</p>\n<p>1&#8239;g every 2&#8239;weeks for 3 doses (loading dose), then (by intravenous infusion) 1&#8239;g every 4&#8239;weeks, alternatively (by subcutaneous injection) 125&#8239;mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65312\" outputclass=\"contraindications\" rev=\"1.9\" parent=\"/drugs/abatacept\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Severe infection</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65331\" outputclass=\"cautions\" rev=\"1.38\" parent=\"/drugs/abatacept\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Do not initiate until active infections are controlled</ph>; <ph outputclass=\"caution\">elderly (increased risk of side-effects)</ph>; <ph outputclass=\"caution\">predisposition to infection (screen for latent tuberculosis and viral hepatitis)</ph>; <ph outputclass=\"caution\">progressive multifocal leucoencephalopathy (discontinue treatment if neurological symptoms present)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65225\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/abatacept\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (abatacept).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65165\" outputclass=\"sideEffects\" rev=\"1.16\" parent=\"/drugs/abatacept\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">conjunctivitis</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">fatigue</ph>; <ph outputclass=\"sideEffect\">flushing</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">infection</ph>; <ph outputclass=\"sideEffect\">leucopenia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">pain in extremities</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">stomatitis</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Psoriasis</ph>; <ph outputclass=\"sideEffect\">alopecia</ph>; <ph outputclass=\"sideEffect\">anxiety</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">basal and squamous cell carcinoma</ph>; <ph outputclass=\"sideEffect\">bradycardia</ph>; <ph outputclass=\"sideEffect\">bronchospasm</ph>; <ph outputclass=\"sideEffect\">bruising</ph>; <ph outputclass=\"sideEffect\">depression</ph>; <ph outputclass=\"sideEffect\">dry eye</ph>; <ph outputclass=\"sideEffect\">dry skin</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">gastritis</ph>; <ph outputclass=\"sideEffect\">hyperhidrosis</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">menstrual disturbances</ph>; <ph outputclass=\"sideEffect\">palpitation</ph>; <ph outputclass=\"sideEffect\">skin papilloma</ph>; <ph outputclass=\"sideEffect\">sleep disorder</ph>; <ph outputclass=\"sideEffect\">tachycardia</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">visual disturbance</ph>; <ph outputclass=\"sideEffect\">weight gain</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Lung cancer</ph>; <ph outputclass=\"sideEffect\">lymphoma</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65318\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/abatacept\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Effective contraception required during treatment and for 14 weeks after last dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65219\" outputclass=\"pregnancy\" parent=\"/drugs/abatacept\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65357\" outputclass=\"breastFeeding\" parent=\"/drugs/abatacept\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in milk in <i>animal</i> studies&#8212;manufacturer advises avoid breast-feeding during treatment and for 14 weeks after last dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65378\" outputclass=\"directionsForAdministration\" rev=\"1.19\" parent=\"/drugs/abatacept\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>For <i>intravenous infusion</i>, reconstitute each vial with 10&#8239;mL water for injections using the silicone-free syringe provided; dilute requisite dose in Sodium Chloride 0.9% to 100&#8239;mL (using the same silicone-free syringe); give over 30 minutes through a low protein-binding filter (pore size 0.2&#8211;1.2&#8239;micron).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65050\" outputclass=\"nationalFunding\" rev=\"1.23\" parent=\"/drugs/abatacept\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA195</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) </p>\r\n<p>Abatacept, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other disease-modifying antirheumatic drugs (DMARDs) including at least 1 tumour necrosis factor (TNF) inhibitor, and who cannot use rituximab because of contra-indications or intolerance. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA195\">www.nice.org.uk/TA195</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA280</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying antirheumatic drugs (April 2013)</p>\r\n<p>Abatacept, in combination with methotrexate, is an option for the treatment of highly active rheumatoid arthritis in adults who have had an inadequate response to at least two conventional disease-modifying antirheumatic drugs, including methotrexate, if:</p>\r\n<ul>\r\n<li> abatacept is used as described in the NICE guidance (October 2007) for other tumour necrosis factor (TNF) inhibitors (see Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis, <i>and</i>\r\n</li>\r\n<li>the manufacturer provides abatacept with the discount agreed in the patient access scheme </li>\r\n</ul>\r\n<p>Patients already receiving abatacept for this indication, who do not fulfil the criteria for treatment should continue treatment until they and their specialist consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA280\">www.nice.org.uk/TA280</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (July 2013) that abatacept (<i>Orencia</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for adults with severe active rheumatoid arthritis, confirmed on at least two occasions, one month apart. This advice is contingent upon continuing availability of abatacept at the price agreed in the patient access scheme.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP6626-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/abatacept\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76781\" title=\"Solution for injection\" namespace=\"/drugs/abatacept/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76774\" title=\"Powder for solution for infusion\" namespace=\"/drugs/abatacept/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78421\" namespace=\"/treatment-summaries/rheumatic-disease-suppressing-drugs\" title=\"Rheumatic disease, suppressing drugs\" count=\"2\" rel=\"backlink\">Rheumatic disease, suppressing drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1095\" namespace=\"/interactions/list-of-drug-interactions/abatacept\" title=\"Abatacept\" count=\"1\" rel=\"link\">Abatacept</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76781\" namespace=\"/drugs/abatacept/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76774\" namespace=\"/drugs/abatacept/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP6626",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/abatacept",
    "basename": "abatacept",
    "title": "ABATACEPT",
    "interactants": [
        {
            "id": "bnf_int_1095",
            "label": "Abatacept"
        }
    ],
    "vtmid": "421412005",
    "drugClassification": [
        "T-cell activation inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Moderate to severe active rheumatoid arthritis (in combination with methotrexate) in patients unresponsive to other disease-modifying antirheumatic drugs (including methotrexate or a tumour necrosis factor (TNF) inhibitor)",
                        "html": "Moderate to severe active rheumatoid arthritis (in combination with methotrexate) in patients unresponsive to other disease-modifying antirheumatic drugs (including methotrexate or a tumour necrosis factor (TNF) inhibitor)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous infusion"
                    ],
                    "textContent": "Initially by intravenous infusion",
                    "html": "Initially by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "500 mg every 2 weeks for 3 doses (loading dose), then (by intravenous infusion) 500 mg every 4 weeks, alternatively (by subcutaneous injection) 125 mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose.",
                        "html": "<p>500&#8239;mg every 2&#8239;weeks for 3 doses (loading dose), then (by intravenous infusion) 500&#8239;mg every 4&#8239;weeks, alternatively (by subcutaneous injection) 125&#8239;mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose.</p>",
                        "ageGroup": "(body-weight up to 60 kg)"
                    },
                    {
                        "textContent": "750 mg every 2 weeks for 3 doses (loading dose), then (by intravenous infusion) 750 mg every 4 weeks, alternatively (by subcutaneous injection) 125 mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose.",
                        "html": "<p>750&#8239;mg every 2&#8239;weeks for 3 doses (loading dose), then (by intravenous infusion) 750&#8239;mg every 4&#8239;weeks, alternatively (by subcutaneous injection) 125&#8239;mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose.</p>",
                        "ageGroup": "(body-weight 60&#8211;100 kg)"
                    },
                    {
                        "textContent": "1 g every 2 weeks for 3 doses (loading dose), then (by intravenous infusion) 1 g every 4 weeks, alternatively (by subcutaneous injection) 125 mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose.",
                        "html": "<p>1&#8239;g every 2&#8239;weeks for 3 doses (loading dose), then (by intravenous infusion) 1&#8239;g every 4&#8239;weeks, alternatively (by subcutaneous injection) 125&#8239;mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose.</p>",
                        "ageGroup": "(body-weight 101 kg and above)"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Severe infection",
                "html": "Severe infection"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Do not initiate until active infections are controlled",
                "html": "Do not initiate until active infections are controlled"
            },
            {
                "type": "cautions",
                "textContent": "elderly (increased risk of side-effects)",
                "html": "elderly (increased risk of side-effects)"
            },
            {
                "type": "cautions",
                "textContent": "predisposition to infection (screen for latent tuberculosis and viral hepatitis)",
                "html": "predisposition to infection (screen for latent tuberculosis and viral hepatitis)"
            },
            {
                "type": "cautions",
                "textContent": "progressive multifocal leucoencephalopathy (discontinue treatment if neurological symptoms present)",
                "html": "progressive multifocal leucoencephalopathy (discontinue treatment if neurological symptoms present)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (abatacept).",
                "html": "<p>Appendix 1 (abatacept).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "conjunctivitis",
                        "html": "conjunctivitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fatigue",
                        "html": "fatigue",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "flushing",
                        "html": "flushing",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "infection",
                        "html": "infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "leucopenia",
                        "html": "leucopenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pain in extremities",
                        "html": "pain in extremities",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "stomatitis",
                        "html": "stomatitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Psoriasis",
                        "html": "Psoriasis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "alopecia",
                        "html": "alopecia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "anxiety",
                        "html": "anxiety",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "basal and squamous cell carcinoma",
                        "html": "basal and squamous cell carcinoma",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "bradycardia",
                        "html": "bradycardia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "bronchospasm",
                        "html": "bronchospasm",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "bruising",
                        "html": "bruising",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "depression",
                        "html": "depression",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dry eye",
                        "html": "dry eye",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dry skin",
                        "html": "dry skin",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gastritis",
                        "html": "gastritis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hyperhidrosis",
                        "html": "hyperhidrosis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "menstrual disturbances",
                        "html": "menstrual disturbances",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "palpitation",
                        "html": "palpitation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "skin papilloma",
                        "html": "skin papilloma",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "sleep disorder",
                        "html": "sleep disorder",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "tachycardia",
                        "html": "tachycardia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "visual disturbance",
                        "html": "visual disturbance",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "weight gain",
                        "html": "weight gain",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Lung cancer",
                        "html": "Lung cancer",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "lymphoma",
                        "html": "lymphoma",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Effective contraception required during treatment and for 14 weeks after last dose.",
                "html": "<p>Effective contraception required during treatment and for 14 weeks after last dose.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless essential.",
                "html": "<p>Manufacturer advises avoid unless essential.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in milk in animal studies&#8212;manufacturer advises avoid breast-feeding during treatment and for 14 weeks after last dose.",
                "html": "<p>Present in milk in <i>animal</i> studies&#8212;manufacturer advises avoid breast-feeding during treatment and for 14 weeks after last dose.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "For intravenous infusion, reconstitute each vial with 10 mL water for injections using the silicone-free syringe provided; dilute requisite dose in Sodium Chloride 0.9% to 100 mL (using the same silicone-free syringe); give over 30 minutes through a low protein-binding filter (pore size 0.2&#8211;1.2 micron).",
                "html": "<p>For <i>intravenous infusion</i>, reconstitute each vial with 10&#8239;mL water for injections using the silicone-free syringe provided; dilute requisite dose in Sodium Chloride 0.9% to 100&#8239;mL (using the same silicone-free syringe); give over 30 minutes through a low protein-binding filter (pore size 0.2&#8211;1.2&#8239;micron).</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA195",
                        "label": "www.nice.org.uk/TA195"
                    }
                ],
                "fundingIdentifier": "NICE TA195",
                "textContent": "Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) Abatacept, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other disease-modifying antirheumatic drugs (DMARDs) including at least 1 tumour necrosis factor (TNF) inhibitor, and who cannot use rituximab because of contra-indications or intolerance. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.\n\nwww.nice.org.uk/TA195",
                "html": "<p outputclass=\"title\">Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) </p> <p>Abatacept, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other disease-modifying antirheumatic drugs (DMARDs) including at least 1 tumour necrosis factor (TNF) inhibitor, and who cannot use rituximab because of contra-indications or intolerance. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA195\">www.nice.org.uk/TA195</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA280",
                        "label": "www.nice.org.uk/TA280"
                    }
                ],
                "fundingIdentifier": "NICE TA280",
                "textContent": "Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying antirheumatic drugs (April 2013) Abatacept, in combination with methotrexate, is an option for the treatment of highly active rheumatoid arthritis in adults who have had an inadequate response to at least two conventional disease-modifying antirheumatic drugs, including methotrexate, if: abatacept is used as described in the NICE guidance (October 2007) for other tumour necrosis factor (TNF) inhibitors (see Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis, and the manufacturer provides abatacept with the discount agreed in the patient access scheme Patients already receiving abatacept for this indication, who do not fulfil the criteria for treatment should continue treatment until they and their specialist consider it appropriate to stop.\n\nwww.nice.org.uk/TA280",
                "html": "<p outputclass=\"title\">Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying antirheumatic drugs (April 2013)</p> <p>Abatacept, in combination with methotrexate, is an option for the treatment of highly active rheumatoid arthritis in adults who have had an inadequate response to at least two conventional disease-modifying antirheumatic drugs, including methotrexate, if:</p> <ul> <li> abatacept is used as described in the NICE guidance (October 2007) for other tumour necrosis factor (TNF) inhibitors (see Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis, <i>and</i> </li> <li>the manufacturer provides abatacept with the discount agreed in the patient access scheme </li> </ul> <p>Patients already receiving abatacept for this indication, who do not fulfil the criteria for treatment should continue treatment until they and their specialist consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA280\">www.nice.org.uk/TA280</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76781",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76774",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78421",
                "label": "Rheumatic disease, suppressing drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1095",
                "label": "Abatacept",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76781",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76774",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}